Blackletter
Group
Welcome
"As a former Corporate VC and Pharma VP, I founded Blackletter to help senior pharma executives get exposure to real and actionable digital innovations and successfully bring them into the 'core' pharma business. My team of 20 consultants helps you navigate the challenge of showing the rest of the organization the tangible business impact of digital without the hype. It's not easy, but with patience, grit and a creative and entrepreneurial drive, it can be done."
Miron Derchansky (MBA, PhD)
Founder and Managing Director, Blackletter Group
We work with some of the most sophisticated executives. We love delighting them
Digital Therapeutics
Assessed the scientific validity and commercial opportunity of 85 digital therapeutics, leading to an entry-path recommendation for the client
Digital Biomarkers
Uncovered 45 predictive digital biomarkers across three therapeutic areas, resulting in 3 co-development pilots
Digital Ecosystem Access
Provided rapid access to innovation ecosystems in Israel, Singapore, Toronto and Silicon Valley and mapped 120 relevant digital technologies
Horizon Scan and Pilots
Identified five 'around the corner' emerging digital opportunity spaces and set up 8 pilots for rapid testing, learning and co-development
Digital Innovation Lab
Launched a Digital Health Innovation Lab in Toronto, Tel Aviv, Boston, Silicon Valley and China resutling in 25 digital projects, investments and spinouts
Medication Adherence Tools
Scouted and piloted adherence technology for both clinical trials and real-world use cases, resulting in 5 partnerships and co-development deals
Digitizing the Value Chain
Diagnosed the full pharma value chain and recommended 5 opportunity areas for near-term digitization and revenue generation potential
Digital Launch
Created a Go-to-Market strategy for a Pharma company that recently-acquired a software business and needed to drive revenues quickly
Stealth Mode Scouting
Uncovered 49 stealth-mode companies that were not on any databases and created informational arbitrage for future partnerships and investments
Cross-Industry Deep Tech
Utilized non-pharma technologies like voicetech and eye-tracking to uncover new biomarkers and therapeutics for novel pharma use cases